# Kriya Therapeutics

**Canonical:** https://apis.io/providers/kriya-therapeutics/  
**Website:** https://kriyatherapeutics.com/  
**APIs profiled:** 10

Kriya Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2019 that designs, develops and manufactures one-time AAV gene therapies for chronic diseases that affect large patient populations, rather than for ultra-rare indications alone. It is headquartered at 1219 Shiloh Glenn Drive in Durham, North Carolina, inside Research Triangle Park, with additional operations in Palo Alto, California, and has raised more than $900 million across Series A ($80M, 2020), Series B ($100M, 2021), Series C (over $430M including a $150M extension, 2022-2023) and Series D ($320M, September 2025). Its pipeline spans three therapeutic areas: ophthalmology (geographic atrophy, thyroid eye disease including KRIYA-586), metabolic disease (Type 1 diabetes, MASH/NASH, an investigational AAV-FGF21 program) and neurology (trigeminal neuralgia, added through the 2022 acquisition of Redpin Therapeutics). The company operates a vertically integrated engine that pairs computational product design with in-house GMP manufacturing — the same unit operations from 1L research scale through 50L, 500L and 3,000L bioreactor scale, with Akta chromatography purification, vial filling and in-house analytical characterization of critical quality attributes. It was selected for the FDA PreCheck Pilot Program in June 2026. Kriya Therapeutics runs no developer program and publishes no product API, no developer portal and no API documentation; the only machine-readable surface reachable without credentials is the WordPress REST content API behind kriyatherapeutics.com, catalogued here.

## Kin Score — 30.6 / 100 (thin)

Scored 2026-08-12 under rubric 0.11.0. Trend: flat (+0.0 from 30.6).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 53.4 |
| Governance | 11.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 16.8 |
| Commercial Clarity | 21.1 |

Regulatory layer — **Health**: 31.3 (matched via tags).

## Agent readiness — 33.1 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | yes |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | partial |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## APIs (10)

- **Kriya Therapeutics Discovery API** — Route, type, taxonomy and status discovery documents.
- **Kriya Therapeutics Forms API** — The `gutena_forms` custom post type used for the site contact form.
- **Kriya Therapeutics Media API** — Media library (304 attachments at harvest time).
- **Kriya Therapeutics News API** — The `news` custom post type — the company press-release archive (28 items at harvest, back to May 2020).
- **Kriya Therapeutics Oembed API** — oEmbed 1.0 provider endpoint for kriyatherapeutics.com URLs.
- **Kriya Therapeutics Pages API** — Corporate and pipeline pages (18 published at harvest time).
- **Kriya Therapeutics Posts API** — Core blog/post collection (33 items at harvest).
- **Kriya Therapeutics Search API** — Cross-content search across published objects.
- **Kriya Therapeutics Taxonomy API** — Categories, tags, news categories and team keywords.
- **Kriya Therapeutics Team API** — The `team` custom post type. Registered and reachable, but empty (X-WP-Total 0) — the Team page is authored as page markup.

## Security (2)

- **Kriya Therapeutics Authentication** — none/apiKey/http · 3 schemes
- **Kriya Therapeutics Domain Security** — TLSv1.3

## Tags

Company, biotechnology, pharmaceuticals, gene-therapy, aav, ophthalmology, metabolic-disease, neurology, life-sciences, clinical-trials, biomanufacturing, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/kriya-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.